07 September 2021: Original Paper
Sofosbuvir/Velpatasvir Prophylaxis for 12 Weeks in Hepatitis C Virus (HCV)-Negative Recipients Receiving Kidney Transplantation from HCV-Positive Donors
Ruoyang Chen BCEF* , Dawei Li BCDFG* , Ming Zhang AC , Xiaodong Yuan ADEF*DOI: 10.12659/AOT.933313
Ann Transplant 2021; 26:e933313
Table 3 Safety.
| Sofosbuvir/Velpatasvir 12 weeks (n=26) | |
|---|---|
| Any adverse event | 15 |
| 3/4 treatment-emergent adverse events | 0 |
| Severe adverse event | 0 |
| Deaths | 0 |
| Adverse events occurring in ≥10% of patients | |
| DGF | 6 |
| Rejection | 3 |
| Heart disease | 3 |
| Bleeding | 3 |
| DGF – delayed graft function. | |